{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:48:41Z","timestamp":1793652521969,"version":"4.5.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["ALZ201912009641"],"award-info":[{"award-number":["ALZ201912009641"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["LabEx DISTALZ ANR-11-LABX-01"],"award-info":[{"award-number":["LabEx DISTALZ ANR-11-LABX-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["RiboTAUxic ANR-21-CE12-0028-01"],"award-info":[{"award-number":["RiboTAUxic ANR-21-CE12-0028-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003750","name":"Association France Alzheimer","doi-asserted-by":"publisher","award":["AAP PFA 2024 - Dossier #6469"],"award-info":[{"award-number":["AAP PFA 2024 - Dossier #6469"]}],"id":[{"id":"10.13039\/501100003750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015760","name":"Inserm Transfert","doi-asserted-by":"publisher","award":["MAT-PI-14188-A-01"],"award-info":[{"award-number":["MAT-PI-14188-A-01"]}],"id":[{"id":"10.13039\/501100015760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015760","name":"Inserm Transfert","doi-asserted-by":"publisher","award":["MAT-PI-18399-A-03"],"award-info":[{"award-number":["MAT-PI-18399-A-03"]}],"id":[{"id":"10.13039\/501100015760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014161","name":"Conseil R\u00e9gional Hauts-de-France","doi-asserted-by":"publisher","award":["Start-AIRR 2016-06656"],"award-info":[{"award-number":["Start-AIRR 2016-06656"]}],"id":[{"id":"10.13039\/501100014161","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tauopathies are a group of neurodegenerative diseases, including Alzheimer\u2019s disease (AD), characterized by progressive accumulation of pathological Tau proteins. Among the diverse Tau species, truncated variants are emerging as key contributors, yet their identity remains elusive, particularly for the N-terminal truncated ones. The present study identifies and characterizes a novel N-terminally truncated and N-alpha-acetylated form of the Tau protein, named AcMet11-Tau.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified AcMet11-Tau by further analyses of previous proteomic data (capillary liquid chromatography-tandem mass spectrometry). We developed a monoclonal antibody, termed 2H2D11, by hybridoma method. The specificity of 2H2D11 was validated by ELISA, Western blot and immunohistochemistry. Expression of AcMet11-Tau in transgenic mouse model of Tau pathology and postmortem brain tissues was analyzed by ELISA and\/or immunohistochemistry. Overexpression of AcMet11-Tau in the mouse brain was achieved by stereotaxic injections of lentiviral vectors carrying the coding sequence in the hippocampus. To neutralize AcMet11-Tau, transgenic mice received repeated intraperitoneal immunizations with either 2H2D11 or control antibody. The effects on Tau pathology were assessed by immunohistochemistry, qPCR, and behavioral assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using 2H2D11, the newly developed antibody specifically targeting the AcMet11-Tau variant, we demonstrated that this species accumulated early in degenerating neurons in both transgenic mouse models of AD-related Tau pathology and post-mortem brain tissues from AD patients. Importantly, in vivo functional experiments revealed that expression of this truncated Tau species exacerbated Tau pathology in the transgenic mice, whereas targeted immunotherapeutic with the specific 2H2D11 antibody significantly reduced pathological Tau accumulation and prevented associated memory impairments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings position this newly identified Tau variant as a marker of neurofibrillary degeneration and a Tau species that contributes to disease-associated pathological processes, supporting its potential as a therapeutic target in Tau-related disorders, notably AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40035-026-00550-8","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:33:46Z","timestamp":1777293226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["N-terminally acetylated Met11-Tau: a new pathological truncated Tau species with functional relevance in Alzheimer's disease"],"prefix":"10.1186","volume":"15","author":[{"given":"Sarah","family":"Guedjdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coline","family":"Leghay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Derisbourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiha","family":"Eddarkaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lecerf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Vermon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaelle","family":"Caillierez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Begard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Regost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Laloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo J.","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Chiappetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Bu\u00e9e-Scherrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Deramecourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Schraen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Bu\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Hamdane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"550_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13024-015-0025-8","volume":"10","author":"M-L Caillet-Boudin","year":"2015","unstructured":"Caillet-Boudin M-L, Bu\u00e9e L, Sergeant N, Lefebvre B. Regulation of human MAPT gene expression. Mol Neurodegener. 2015;10:28.","journal-title":"Mol Neurodegener"},{"key":"550_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1039\/D1CS00127B","volume":"51","author":"G Limorenko","year":"2022","unstructured":"Limorenko G, Lashuel HA. Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies. Chem Soc Rev. 2022;51:513\u201365.","journal-title":"Chem Soc Rev"},{"key":"550_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak H, Braak E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271\u20138 (discussion 278-284).","journal-title":"Neurobiol Aging"},{"key":"550_CR4","first-page":"180","volume":"98","author":"C Duyckaerts","year":"1998","unstructured":"Duyckaerts C, Colle MA, Dessi F, Piette F, Hauw JJ. Progression of Alzheimer histopathological changes. Acta Neurol Belg. 1998;98:180\u20135.","journal-title":"Acta Neurol Belg"},{"key":"550_CR5","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","volume":"52","author":"A Delacourte","year":"1999","unstructured":"Delacourte A, David JP, Sergeant N, Bu\u00e9e L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer\u2019s disease. Neurology. 1999;52:1158\u201365.","journal-title":"Neurology"},{"key":"550_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1042\/BST20120015","volume":"40","author":"N Zilka","year":"2012","unstructured":"Zilka N, Kovacech B, Barath P, Kontsekova E, Nov\u00e1k M. The self-perpetuating tau truncation circle. Biochem Soc Trans. 2012;40:681\u20136.","journal-title":"Biochem Soc Trans"},{"key":"550_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-170959","volume":"63","author":"JP Quinn","year":"2018","unstructured":"Quinn JP, Corbett NJ, Kellett KAB, Hooper NM. Tau proteolysis in the pathogenesis of tauopathies: neurotoxic fragments and novel biomarkers. J Alzheimers Dis. 2018;63:13\u201333.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"550_CR8","doi-asserted-by":"publisher","first-page":"165584","DOI":"10.1016\/j.bbadis.2019.165584","volume":"1866","author":"G Amadoro","year":"2020","unstructured":"Amadoro G, Latina V, Corsetti V, Calissano P. N-terminal tau truncation in the pathogenesis of Alzheimer\u2019s disease (AD): developing a novel diagnostic and therapeutic approach. Biochim Biophys Acta Mol Basis Dis. 2020;1866(3):165584.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"550_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fnagi.2018.00027","volume":"10","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Shi J, Chu D, Hu W, Guan Z, Gong C-X, et al. Relevance of phosphorylation and truncation of tau to the etiopathogenesis of alzheimer\u2019s disease. Front Aging Neurosci. 2018;10:27.","journal-title":"Front Aging Neurosci"},{"key":"550_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/biomedicines10020241","volume":"10","author":"PJ da Costa","year":"2022","unstructured":"da Costa PJ, Hamdane M, Bu\u00e9e L, Martin F. Tau mRNA metabolism in neurodegenerative diseases: a tangle journey. Biomedicines. 2022;10:241.","journal-title":"Biomedicines"},{"key":"550_CR11","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1038\/srep09659","volume":"5","author":"M Derisbourg","year":"2015","unstructured":"Derisbourg M, Leghay C, Chiappetta G, Fernandez-Gomez F-J, Laurent C, Demeyer D, et al. Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep. 2015;5:9659.","journal-title":"Sci Rep"},{"key":"550_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/ana.10163","volume":"51","author":"S Hayashi","year":"2002","unstructured":"Hayashi S, Toyoshima Y, Hasegawa M, Umeda Y, Wakabayashi K, Tokiguchi S, et al. Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) Tau gene mutation. Ann Neurol. 2002;51:525\u201330.","journal-title":"Ann Neurol"},{"key":"550_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ana.10340","volume":"52","author":"P Poorkaj","year":"2002","unstructured":"Poorkaj P, Muma NA, Zhukareva V, Cochran EJ, Shannon KM, Hurtig H, et al. An R5L Tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol. 2002;52:511\u20136.","journal-title":"Ann Neurol"},{"key":"550_CR14","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1038\/sj.emboj.7601878","volume":"26","author":"E Magnani","year":"2007","unstructured":"Magnani E, Fan J, Gasparini L, Golding M, Williams M, Schiavo G, et al. Interaction of Tau protein with the dynactin complex. EMBO J. 2007;26:4546\u201354.","journal-title":"EMBO J"},{"key":"550_CR15","doi-asserted-by":"publisher","first-page":"32789","DOI":"10.1074\/jbc.271.51.32789","volume":"271","author":"G Carmel","year":"1996","unstructured":"Carmel G, Mager EM, Binder LI, Kuret J. The structural basis of monoclonal antibody Alz50\u2019s selectivity for Alzheimer\u2019s disease pathology. J Biol Chem. 1996;271:32789\u201395.","journal-title":"J Biol Chem"},{"key":"550_CR16","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1021\/bi0521543","volume":"45","author":"S Jeganathan","year":"2006","unstructured":"Jeganathan S, von Bergen M, Brutlach H, Steinhoff H-J, Mandelkow E. Global hairpin folding of Tau in solution. Biochemistry. 2006;45:2283\u201393.","journal-title":"Biochemistry"},{"key":"550_CR17","doi-asserted-by":"publisher","first-page":"32066","DOI":"10.1074\/jbc.M805300200","volume":"283","author":"S Jeganathan","year":"2008","unstructured":"Jeganathan S, Hascher A, Chinnathambi S, Biernat J, Mandelkow E-M, Mandelkow E. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J Biol Chem. 2008;283:32066\u201376.","journal-title":"J Biol Chem"},{"key":"550_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0006-291X(03)01316-0","volume":"308","author":"B Polevoda","year":"2003","unstructured":"Polevoda B, Sherman F. Composition and function of the eukaryotic N-terminal acetyltransferase subunits. Biochem Biophys Res Commun. 2003;308:1\u201311.","journal-title":"Biochem Biophys Res Commun"},{"key":"550_CR19","doi-asserted-by":"publisher","first-page":"8157","DOI":"10.1073\/pnas.0901931106","volume":"106","author":"T Arnesen","year":"2009","unstructured":"Arnesen T, Van Damme P, Polevoda B, Helsens K, Evjenth R, Colaert N, et al. Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proc Natl Acad Sci U S A. 2009;106:8157\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"550_CR20","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.bbapap.2016.06.007","volume":"1864","author":"A Drazic","year":"2016","unstructured":"Drazic A, Myklebust LM, Ree R, Arnesen T. The world of protein acetylation. Biochim Biophys Acta. 2016;1864:1372\u2013401.","journal-title":"Biochim Biophys Acta"},{"key":"550_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/febs.17209","volume":"292","author":"S Calis","year":"2025","unstructured":"Calis S, Gevaert K. The role of N\u03b1\u2010terminal acetylation in protein conformation. FEBS J. 2025;292:453\u201367.","journal-title":"FEBS J"},{"key":"550_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41467-025-55960-5","volume":"16","author":"N McTiernan","year":"2025","unstructured":"McTiernan N, Kjos\u00e5s I, Arnesen T. Illuminating the impact of N-terminal acetylation: from protein to physiology. Nat Commun. 2025;16:703.","journal-title":"Nat Commun"},{"key":"550_CR23","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"key":"550_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2353\/ajpath.2006.060002","volume":"169","author":"K Schindowski","year":"2006","unstructured":"Schindowski K, Bretteville A, Leroy K, B\u00e9gard S, Brion J-P, Hamdane M, et al. Alzheimer\u2019s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169:599\u2013616.","journal-title":"Am J Pathol"},{"key":"550_CR25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3233\/JAD-130110","volume":"37","author":"A Van der Jeugd","year":"2013","unstructured":"Van der Jeugd A, Vermaercke B, Derisbourg M, Lo AC, Hamdane M, Blum D, et al. Progressive age-related cognitive decline in tau mice. J Alzheimers Dis. 2013;37:777\u201388.","journal-title":"J Alzheimers Dis"},{"key":"550_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/brain\/aww270","volume":"140","author":"C Laurent","year":"2017","unstructured":"Laurent C, Doroth\u00e9e G, Hunot S, Martin E, Monnet Y, Duchamp M, et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain. 2017;140:184\u2013200.","journal-title":"Brain"},{"key":"550_CR27","doi-asserted-by":"publisher","first-page":"976","DOI":"10.2353\/ajpath.2007.070345","volume":"171","author":"K Leroy","year":"2007","unstructured":"Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, et al. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol. 2007;171:976\u201392.","journal-title":"Am J Pathol"},{"key":"550_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1749-6632.2000.tb06911.x","volume":"920","author":"C Mailliot","year":"2000","unstructured":"Mailliot C, Bussi\u00e8re T, Hamdane M, Sergeant N, Caillet M-L, Delacourte A, et al. Pathological tau phenotypes: the weight of mutations, polymorphisms, and differential neuronal vulnerabilities. Ann N Y Acad Sci. 2000;920:107\u201314.","journal-title":"Ann N Y Acad Sci"},{"key":"550_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/10430340050016256","volume":"11","author":"N Deglon","year":"2000","unstructured":"Deglon N, Tseng JL, Bensadoun J-C, Zurn AD, Arsenijevic Y, Almeida LPD, et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson\u2019s disease. Human Gene Therapy. 2000;11:179\u201390.","journal-title":"Human Gene Therapy"},{"key":"550_CR30","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/mt.2013.66","volume":"21","author":"R Caillierez","year":"2013","unstructured":"Caillierez R, B\u00e9gard S, L\u00e9colle K, Deramecourt V, Zommer N, Dujardin S, et al. Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain. Mol Ther. 2013;21:1358.","journal-title":"Mol Ther"},{"key":"550_CR31","doi-asserted-by":"publisher","first-page":"34026","DOI":"10.1074\/jbc.M302872200","volume":"278","author":"M Hamdane","year":"2003","unstructured":"Hamdane M, Sambo A-V, Delobel P, B\u00e9gard S, Violleau A, Delacourte A, et al. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem. 2003;278:34026\u201334.","journal-title":"J Biol Chem"},{"key":"550_CR32","doi-asserted-by":"publisher","first-page":"102386","DOI":"10.1016\/j.pneurobio.2022.102386","volume":"223","author":"M Denechaud","year":"2023","unstructured":"Denechaud M, Geurs S, Comptdaer T, B\u00e9gard S, Garcia-N\u00fa\u00f1ez A, Pechereau L-A, et al. Tau promotes oxidative stress-associated cycling neurons in S phase as a pro-survival mechanism: possible implication for Alzheimer\u2019s disease. Prog Neurobiol. 2023;223:102386.","journal-title":"Prog Neurobiol"},{"key":"550_CR33","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol Y, Bandla C, Kundu DJ, Kamatchinathan S, Bai J, Hewapathirana S, et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 2025;53:D543\u201353.","journal-title":"Nucleic Acids Res"},{"key":"550_CR34","first-page":"88","volume":"1","author":"S Pandey","year":"2010","unstructured":"Pandey S. Hybridoma technology for production of monoclonal antibodies. Int J Pharm Sci Rev Res. 2010;1:88\u201394.","journal-title":"Int J Pharm Sci Rev Res"},{"key":"550_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0022-1759(99)00122-2","volume":"230","author":"M Trebak","year":"1999","unstructured":"Trebak M, Chong JM, Herlyn D, Speicher DW. Efficient laboratory-scale production of monoclonal antibodies using membrane-based high-density cell culture technology. J Immunol Methods. 1999;230:59\u201370.","journal-title":"J Immunol Methods"},{"issue":"1","key":"550_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/jps.22267","volume":"100","author":"LA Brito","year":"2011","unstructured":"Brito LA, Singh M. Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci. 2011;100(1):34\u20137.","journal-title":"J Pharm Sci"},{"key":"550_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13024-017-0172-1","volume":"12","author":"MG Agadjanyan","year":"2017","unstructured":"Agadjanyan MG, Zagorski K, Petrushina I, Davtyan H, Kazarian K, Antonenko M, et al. Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. Mol Neurodegener. 2017;12:33.","journal-title":"Mol Neurodegener"},{"key":"550_CR38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0197-4580(00)00157-3","volume":"21","author":"CL Weaver","year":"2000","unstructured":"Weaver CL, Espinoza M, Kress Y, Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer\u2019s disease. Neurobiol Aging. 2000;21:719\u201327.","journal-title":"Neurobiol Aging"},{"key":"550_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s004010100423","volume":"103","author":"JC Augustinack","year":"2002","unstructured":"Augustinack JC, Schneider A, Mandelkow E-M, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer\u2019s disease. Acta Neuropathol. 2002;103:26\u201335.","journal-title":"Acta Neuropathol"},{"key":"550_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/mp.2014.151","volume":"21","author":"C Laurent","year":"2016","unstructured":"Laurent C, Burnouf S, Ferry B, Batalha VL, Coelho JE, Baqi Y, et al. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatry. 2016;21:97\u2013107.","journal-title":"Mol Psychiatry"},{"key":"550_CR41","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1093\/brain\/awz288","volume":"142","author":"K Carvalho","year":"2019","unstructured":"Carvalho K, Faivre E, Pietrowski MJ, Marques X, Gomez-Murcia V, Deleau A, et al. Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. Brain. 2019;142:3636\u201354.","journal-title":"Brain"},{"key":"550_CR42","doi-asserted-by":"publisher","first-page":"S535","DOI":"10.3233\/JAD-179942","volume":"64","author":"P Novak","year":"2018","unstructured":"Novak P, Cehlar O, Skrabana R, Novak M. Tau conformation as a target for disease-modifying therapy: the role of truncation. J Alzheimers Dis. 2018;64:S535\u201346.","journal-title":"J Alzheimers Dis"},{"key":"550_CR43","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.4103\/1673-5374.385853","volume":"19","author":"D Chu","year":"2024","unstructured":"Chu D, Yang X, Wang J, Zhou Y, Gu J-H, Miao J, et al. Tau truncation in the pathogenesis of Alzheimer\u2019s disease: a narrative review. Neural Regen Res. 2024;19:1221\u201332.","journal-title":"Neural Regen Res"},{"key":"550_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1172\/JCI200420640","volume":"114","author":"RA Rissman","year":"2004","unstructured":"Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004;114:121\u201330.","journal-title":"J Clin Invest"},{"key":"550_CR45","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/NEN.0b013e31817275c7","volume":"67","author":"G Basurto-Islas","year":"2008","unstructured":"Basurto-Islas G, Luna-Mu\u00f1oz J, Guillozet-Bongaarts AL, Binder LI, Mena R, Garc\u00eda-Sierra F. Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J Neuropathol Exp Neurol. 2008;67:470\u201383.","journal-title":"J Neuropathol Exp Neurol"},{"key":"550_CR46","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/nature08890","volume":"464","author":"A de Calignon","year":"2010","unstructured":"de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, et al. Caspase activation precedes and leads to tangles. Nature. 2010;464:1201\u20134.","journal-title":"Nature"},{"key":"550_CR47","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm.3700","volume":"20","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Song M, Liu X, Kang SS, Kwon I-S, Duong DM, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer\u2019s disease. Nat Med. 2014;20:1254\u201362.","journal-title":"Nat Med"},{"key":"550_CR48","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/nm.4199","volume":"22","author":"X Zhao","year":"2016","unstructured":"Zhao X, Kotilinek LA, Smith B, Hlynialuk C, Zahs K, Ramsden M, et al. Caspase-2 cleavage of tau reversibly impairs memory. Nat Med. 2016;22:1268\u201376.","journal-title":"Nat Med"},{"key":"550_CR49","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/0022-2836(87)90418-9","volume":"196","author":"M Kozak","year":"1987","unstructured":"Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol. 1987;196:947\u201350.","journal-title":"J Mol Biol"},{"key":"550_CR50","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.tibs.2012.02.003","volume":"37","author":"KK Starheim","year":"2012","unstructured":"Starheim KK, Gevaert K, Arnesen T. Protein N-terminal acetyltransferases: when the start matters. Trends Biochem Sci. 2012;37:152\u201361.","journal-title":"Trends Biochem Sci"},{"key":"550_CR51","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/nar\/gkt1035","volume":"42","author":"AM Michel","year":"2014","unstructured":"Michel AM, Fox G, Kiran AM, De Bo C, Oconnor PBF, Heaphy SM, et al. GWIPS-viz: development of a ribo-seq genome browser. Nucleic Acids Res. 2014;42:859\u201364.","journal-title":"Nucleic Acids Res"},{"key":"550_CR52","doi-asserted-by":"publisher","first-page":"ugae023","DOI":"10.1093\/narmme\/ugae023","volume":"1","author":"PJ da Costa","year":"2024","unstructured":"da Costa PJ, Perret A, Bu\u00e9e L, Hamdane M, Martin F. FTLD-MAPT mutations and short 5\u2032UTR Tau mRNAs increase Tau translation. NAR Mol Med. 2024;1:ugae023.","journal-title":"NAR Mol Med"},{"key":"550_CR53","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41580-018-0034-x","volume":"19","author":"S Tahmasebi","year":"2018","unstructured":"Tahmasebi S, Khoutorsky A, Mathews MB, Sonenberg N. Translation deregulation in human disease. Nat Rev Mol Cell Biol. 2018;19:791\u2013807.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"550_CR54","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lfs.2018.09.054","volume":"212","author":"CC James","year":"2018","unstructured":"James CC, Smyth JW. Alternative mechanisms of translation initiation: an emerging dynamic regulator of the proteome in health and disease. Life Sci. 2018;212:138\u201344.","journal-title":"Life Sci"},{"key":"550_CR55","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/ncb801","volume":"4","author":"Y Yin","year":"2002","unstructured":"Yin Y, Stephen CW, Luciani MG, F\u00e5hraeus R. p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol. 2002;4:462\u20137.","journal-title":"Nat Cell Biol"},{"key":"550_CR56","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/cancers11020142","volume":"11","author":"M Jaud","year":"2019","unstructured":"Jaud M, Philippe C, Van Den Berghe L, S\u00e9gura C, Mazzolini L, Pyronnet S, et al. The PERK branch of the unfolded protein response promotes DLL4 expression by activating an alternative translation mechanism. Cancers (Basel). 2019;11:142.","journal-title":"Cancers (Basel)"},{"key":"550_CR57","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.tibs.2019.12.009","volume":"45","author":"A Bogaert","year":"2020","unstructured":"Bogaert A, Fernandez E, Gevaert K. N-terminal proteoforms in human disease. Trends Biochem Sci. 2020;45:308\u201320.","journal-title":"Trends Biochem Sci"},{"key":"550_CR58","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.bbadis.2018.03.022","volume":"1864","author":"H Kwon","year":"2018","unstructured":"Kwon H, Jang D, Choi M, Lee J, Jeong K, Pak Y. Alternative translation initiation of Caveolin-2 desensitizes insulin signaling through dephosphorylation of insulin receptor by PTP1B and causes insulin resistance. Biochim Biophys Acta (BBA). 2018;1864:2169\u201382.","journal-title":"Biochim Biophys Acta (BBA)"},{"key":"550_CR59","doi-asserted-by":"publisher","first-page":"1003997","DOI":"10.3389\/fnins.2022.1003997","volume":"16","author":"A Iyer","year":"2022","unstructured":"Iyer A, Sidhu A, Subramaniam V. How important is the N-terminal acetylation of alpha-synuclein for its function and aggregation into amyloids? Front Neurosci. 2022;16:1003997.","journal-title":"Front Neurosci"},{"key":"550_CR60","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1038\/s41467-023-42342-y","volume":"14","author":"S Varland","year":"2023","unstructured":"Varland S, Silva RD, Kjos\u00e5s I, Faustino A, Bogaert A, Billmann M, et al. N-terminal acetylation shields proteins from degradation and promotes age-dependent motility and longevity. Nat Commun. 2023;14:6774.","journal-title":"Nat Commun"},{"key":"550_CR61","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/mp.2015.228","volume":"21","author":"S Ozcelik","year":"2016","unstructured":"Ozcelik S, Sprenger F, Skachokova Z, Fraser G, Abramowski D, Clavaguera F, et al. Co-expression of truncated and full-length tau induces severe neurotoxicity. Mol Psychiatry. 2016;21:1790\u20138.","journal-title":"Mol Psychiatry"},{"key":"550_CR62","doi-asserted-by":"publisher","first-page":"8124","DOI":"10.1007\/s12035-018-0974-3","volume":"55","author":"A Borreca","year":"2018","unstructured":"Borreca A, Latina V, Corsetti V, Middei S, Piccinin S, Della Valle F, et al. AD-related N-terminal truncated tau is sufficient to recapitulate in vivo the early perturbations of human neuropathology: implications for immunotherapy. Mol Neurobiol. 2018;55:8124\u201353.","journal-title":"Mol Neurobiol"},{"key":"550_CR63","doi-asserted-by":"publisher","first-page":"fcaa039","DOI":"10.1093\/braincomms\/fcaa039","volume":"2","author":"V Corsetti","year":"2020","unstructured":"Corsetti V, Borreca A, Latina V, Giacovazzo G, Pignataro A, Krashia P, et al. Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer\u2019s disease models. Brain Commun. 2020;2:fcaa039.","journal-title":"Brain Commun"},{"key":"550_CR64","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fnins.2018.00267","volume":"12","author":"SL DeVos","year":"2018","unstructured":"DeVos SL, Corjuc BT, Oakley DH, Nobuhara CK, Bannon RN, Chase A, et al. Synaptic tau seeding precedes tau pathology in human Alzheimer\u2019s disease brain. Front Neurosci. 2018;12:267.","journal-title":"Front Neurosci"},{"key":"550_CR65","doi-asserted-by":"publisher","first-page":"102163","DOI":"10.1016\/j.jbc.2022.102163","volume":"298","author":"H Mirbaha","year":"2022","unstructured":"Mirbaha H, Chen D, Mullapudi V, Terpack SJ, White CL, Joachimiak LA, et al. Seed-competent tau monomer initiates pathology in a tauopathy mouse model. J Biol Chem. 2022;298:102163.","journal-title":"J Biol Chem"},{"key":"550_CR66","doi-asserted-by":"publisher","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","volume":"111","author":"BB Holmes","year":"2014","unstructured":"Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A. 2014;111:E4376-4385.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"550_CR67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s40478-023-01676-w","volume":"11","author":"B Frey","year":"2023","unstructured":"Frey B, Holzinger D, Taylor K, Ehrnhoefer DE, Striebinger A, Biesinger S, et al. Tau seed amplification assay reveals relationship between seeding and pathological forms of tau in Alzheimer\u2019s disease brain. Acta Neuropathol Commun. 2023;11:181.","journal-title":"Acta Neuropathol Commun"},{"key":"550_CR68","doi-asserted-by":"publisher","first-page":"104707","DOI":"10.1016\/j.nbd.2019.104707","volume":"134","author":"A Bittar","year":"2020","unstructured":"Bittar A, Bhatt N, Kayed R. Advances and considerations in AD tau-targeted immunotherapy. Neurobiol Dis. 2020;134:104707.","journal-title":"Neurobiol Dis"},{"key":"550_CR69","doi-asserted-by":"publisher","first-page":"108104","DOI":"10.1016\/j.neuropharm.2020.108104","volume":"175","author":"LA Sandusky-Beltran","year":"2020","unstructured":"Sandusky-Beltran LA, Sigurdsson EM. Tau immunotherapies: lessons learned, current status and future considerations. Neuropharmacology. 2020;175:108104.","journal-title":"Neuropharmacology"},{"key":"550_CR70","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2023;19:715\u201336.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"550_CR71","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jnc.12821","volume":"132","author":"A Ittner","year":"2015","unstructured":"Ittner A, Bertz J, Suh LS, Stevens CH, G\u00f6tz J, Ittner LM. Tau\u2010targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem. 2015;132(1):135\u201345.","journal-title":"J Neurochem"},{"key":"550_CR72","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000440842","volume":"16","author":"EM Sigurdsson","year":"2016","unstructured":"Sigurdsson EM. Tau immunotherapy. Neurodegener Dis. 2016;16:34\u20138.","journal-title":"Neurodegener Dis"},{"key":"550_CR73","first-page":"887","volume":"86","author":"ST Nerenberg","year":"1975","unstructured":"Nerenberg ST, Prasad R. Radioimmunoassays for Ig classes G, A, M, D, and E in spinal fluids: normal values of different age groups. J Lab Clin Med. 1975;86:887\u201398.","journal-title":"J Lab Clin Med"},{"key":"550_CR74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2:3\u201314.","journal-title":"NeuroRx"},{"key":"550_CR75","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369.","journal-title":"Alzheimers Dement"},{"key":"550_CR76","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2174\/1570159X01666160930121647","volume":"15","author":"K Manoutcharian","year":"2017","unstructured":"Manoutcharian K, Perez-Garmendia R, Gevorkian G. Recombinant antibody fragments for neurodegenerative diseases. Curr Neuropharmacol. 2017;15:779\u201388.","journal-title":"Curr Neuropharmacol"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-026-00550-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-026-00550-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-026-00550-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:03:28Z","timestamp":1777298608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40035-026-00550-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["550"],"URL":"https:\/\/doi.org\/10.1186\/s40035-026-00550-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.10.03.680200","asserted-by":"object"}]},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Human brain tissue samples were obtained from The Lille NeuroBank collection. The Lille NeuroBank has been declared to the French Research Ministry by the Lille University Hospital (CHU-Lille) on August 14, 2008 under the reference DC-2000-642 and fulfills the criteria defined by French Law regarding biological resources, including informed consent; ethics review committee approval and data protection. The ethical review committee of Lille NeuroBank approved the study. All the experimental protocols involving mice were approved by the CEEA75 ethical committee (12787-2015101320441671v9)\n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LB, MH, DB, MD, CLe, GC, YV are inventors of the patent \u201cWO2018178078A1\u201d: New tau species (2018). MH, LB, DB, SE, SG are inventors of the patent \u201cWO2020193520A1\u201d: Treatment of tauopathy disorders by targeting new tau species (2020). These 2 patents are related to antibodies targeting AcMet11-Tau species. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}